A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 20 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 28 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.